Next Article in Journal
Sino-Austrian High-Tech Acupuncture Network—Annual Report 2016
Next Article in Special Issue
Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer
Previous Article in Journal
Vochysia rufa Stem Bark Extract Protects Endothelial Cells against High Glucose Damage
Previous Article in Special Issue
Add-On Complementary Medicine in Cancer Care: Evidence in Literature and Experiences of Integration
Article Menu

Export Article

Open AccessArticle
Medicines 2017, 4(1), 10; doi:10.3390/medicines4010010

ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially through the GSK3 Pathway

1
Cardiff China Medical Research Collaborative, Cardiff University-Peking University Joint Cancer Institute, Henry Wellcome Building, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
2
Department of Gynaecological Oncology, Peking University Cancer Hospital, Haidian District, Beijing 100142, China
3
Departments of Gynaecology and Medical Oncology, YuHuangDing Hospital, QingDao University, Yantai 266061, China
4
Yiling Medical Research Institute, Shijiazhuang 050000, China
5
State Key Laboratory of Collateral Disease Research and Innovation Medicine, Shijiazhuang 050000, China
6
Key Disciplines of State Administration of TCM for Collateral Disease, Shijiazhuang 050000, China
*
Authors to whom correspondence should be addressed.
Academic Editors: Sivarama Vinjamury and Elizabeth Sommers
Received: 18 November 2016 / Revised: 25 January 2017 / Accepted: 15 February 2017 / Published: 21 February 2017
(This article belongs to the Special Issue Complementary and Alternative Medicine for Cancer Patients)
View Full-Text   |   Download PDF [2742 KB, uploaded 21 February 2017]   |  

Abstract

Background: Ovarian cancer presents a major clinical challenge in the UK. Glycogen synthase kinase-3 (GSK-3) has been linked to cancer. This study tested the impact of ShenLingLan (SLDM) on ovarian cancer cell behaviour and its links to GSK-3. Methods: Fresh ovarian tumours (n = 52) were collected and processed. Histopathologcial and clinical information were collected and analysed against GSK-3 transcript levels using quantitative PCR (qPCR). Immortalised ovarian cancer cells’ protein alterations in response to SLDM were identified using a Kinexus™ protein kinase array. The effects of SLDM and a combination of SLDM and TWS119 on ovarian cancer cells ability to attach and migrate were evaluated using electrical cell-substrate impedance sensing (ECIS). Results: Transcript expression of GSK-3β was significantly increased in ovarian tumours which were poorly differentiated, patients with recurrence and in patients who had died from ovarian cancer. Treating SKOV-3 ovarian cells with SLDM reduced GSK-3 expression and GSK-3α (Y279). Treatment with SLDM reduced ovarian cancer cells ability to attach and migrate, which was further reduced in the presence of TWS119. Conclusions: This study identified a potential mechanism by which SLDM may exert anti-metastatic effects. Further work is needed to investigate the in vivo effects SLDM has on ovarian tumours. View Full-Text
Keywords: ShenLingLan; ovarian cancer; cell migration; GSK3 ShenLingLan; ovarian cancer; cell migration; GSK3
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Owen, S.; Ruge, F.; Gao, Y.; Yang, Y.; Hou, J.; Chen, J.; Feng, Y.; Zhang, H.; Gao, Y.; Wang, H.; Wei, C.; Wu, Y.; Jiang, W.G. ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially through the GSK3 Pathway. Medicines 2017, 4, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top